ABSTRACTS OF THE 21st ANNUAL MEETING OF THE ITALIAN ...

More documents

Recommendations

Info

and response to intravesical treatment has been scarcely studied. Available studies suggest a reduction in recurrence risk with cessation of smoking, however, most studies lack sufficient statistical power. The aim of the present analysis was to study the recurrence risk and the response to intravesical chemotherapy in terms of recurrence-free rate (RFR) and recurrence-free survival (RFS) in relation to smoking status at diagnosis in patients affected by intermediate-risk non-muscle invasive carcinoma of the bladder (NMI-BC). Patients and Methods: Tumor characteristics and smoking status were recorded for patients affected by NMI-BC treated by transurethral resection (TUR) and adjuvant intravesical therapy. All patients received intravesical epirubicin within six hours of TUR at a dose of 80 mg diluted in 50 ml of saline solution. Further adjuvant treatment in low- and high-risk patients was given according to physicians’ choice. Two different schemes of intravesical chemotherapy with epirubicin were adopted at a dose of 80 mg in 50 ml for patients at intermediate risk. All patients were submitted to cytology and cystoscopy at three-monthly intervals for two years and then at six-monthly intervals for three more years. Multivariate statistical analysis was conducted to study the recurrence risk and the response to intravesical chemotherapy in terms of RFR and RFS in relation to smoking status at diagnosis. Results: Out of 577 consecutive patients, 241 (42%), 188 (33%) and 148 (25%) were current, former and never smokers, respectively. The mean number of cigarettes smoked per day was 20 for a median period of 30 years. Recurrent tumors were statistically more frequent in smokers that in never smokers. The percentage of recurrence increased from 20% to 42% (p
Abstracts of the 21st Annual Meeting of the Italian Society of Uro-Oncology (SIUrO), 22-24 June, 2011, Naples, Italy Conclusion: Almost 65% of patients experiencing recurrence after intravesical chemotherapy received intravesical therapy again. No difference in efficacy was detected between firstand second-line therapies or between BCG and chemotherapy given at recurrence after chemotherapy. We wish to thank the GSTU Foundation for the statistical evaluations. 16 MINIMALLY INVASIVE OPEN TUMOR ENUCLEATION VS. PERCUTANEOUS RADIOFREQUENCY ABLATION VS. ACTIVE SURVEILLANCE OF SMALL RENAL MASSES
Page 1 and 2: ANTICANCER RESEARCH 31: 1807-1956 (
Page 3 and 4: ANTICANCER RESEARCH 31: 1807-1956 (
Page 5 and 6: 1Department of Urology, Ospedale Sa
Page 7 and 8: Abstracts of the 21st Annual Meetin
Page 9: Abstracts of the 21st Annual Meetin
Page 61 and 62:
Abstracts of the 21st Annual Meetin
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Table II. Median value 3DCRT V40 V5
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
255 ACCURACY OF ENDORECTAL MRI AND
Page 143 and 144:
Page 145 and 146:
Page 147:
Nucciotti R, 35 Oderda M, 37, 38, 1
show all

ABSTRACTS OF THE 21st ANNUAL MEETING OF THE ITALIAN ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?